This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The assigned 510(k) number is 090964.

# SUBMITTER

Binax, Inc.   
10 Southgate Road   
Scarborough, Maine 04074   
(207) 730-5733 (Office)   
(207) 730-5717 (FAX)   
Establishment Registration Number: 1221359   
CONTACT PERSON   
Suzanne Vogel   
suzanne.vogel@invmed.com (email)

DATE PREPARED December 12, 2009

TRADE NAME BinaxNOW® Staphylococcus aureus Test

COMMON NAME BinaxNOW® Staphylococcus aureus Test, BinaxNOW® Staphylococcus aureus, BinaxNOW® S. aureus, Binax $\widetilde { \mathbf { N O W } } ^ { \otimes }$ Staphylococcus aureus Test, Binax NOW® Staphylococcus aureus, Binax NOW® S. aureus, $\widetilde { \mathbf { N O W } } ^ { \otimes }$ Staphylococcus aureus Test, $\mathrm { { N O W } } ^ { \mathfrak { \left( B \right) } }$ Staphylococcus aureus, $\operatorname { N O W } ^ { \circledast } \operatorname { S }$ aureus

# CLASSIFICATION NAME

Microorganism differentiation and identification device (JWX) (per 21 CFR 866.2660)

PREDICATE DEVICE S. aureus PNA FISHTM (AdvanDx) K#060099

# DEVICE DESCRIPTION

The BinaxNOw® Staphylococcus aureus Test is a rapid immunochromatographic membrane assay that uses highly sensitive polyclonal antibodies to detect a Staphylococcus aureus specific protein directly from blood cultures which have been identified as being positive for Gram-positive cocci in clusters. These antibodies and a control antibody are immobilized onto a test strip as two distinct lines and combined with other reagents/pads. This test strip is mounted inside a cardboard, book-shaped hinged test device.

Specimens are aliquots from blood cultures which have been identified as positive for Gram-positive coci in clusters.After the sample is prepared, it is added to the sample pad at the top of the test srp and the device is closed. Results are read at 10 minutes.

# INTENDED USE

The BinaxNOw® Staphylococcus aureus Test is a qualitative, in vitro immunochromatographic assay for the presumptive identification of Staphylococcus aureus. The test is performed directly on blood culture samples positive for Gram-positive cocci in clusters. The BinaxNOW® Staphylococcus aureus Test is not intended to diagnose Staphylococcus aureus nor to guide or monitor treatment for Staphylococcus aureus infections. Subculturing positive blood cultures is necessary to recover organisms for susceptibility testing and/or differentiation of mixed growth.

# TECHNOLOGICAL CHARACTERISTICS

The BinaxNOw® Staphylococcus aureus Test is a rapid immunochromatographic membrane assay that uses highly sensitive polyclonal antibodies to detect a Staphylococcus aureus specific protein directly from blood cultures bottles positive for Gram-positive cocci in clusters.

# PERFORMANCE SUMMARY

# Clinical Performance

The clinical performance of the BinaxNOW® Staphylococcus aureus Test was established in a multicenter clinical study conducted in 2008-09 at three geographically-diverse hospital laboratories within the US.

A total of 325 blood culture samples with Gram-positive cocci in clusters were evaluated at the three sites in the BinaxNOw® Staphylococcus aureus Test and compared to standard methods used routinely by the testing laboratories. The BinaxNOW® Staphylococcus aureus Test identified $9 8 . 8 \%$ of the specimens positive for Staphylococcus aureus and $1 0 0 . 0 \%$ of the specimens negative for Staphylococcus aureus relative to the reference method.

BinaxNOw® Staphylococcus aureus Test Compared to Reference Method   

<table><tr><td rowspan=1 colspan=2>Reference Method</td></tr><tr><td rowspan=1 colspan=1>BinaxNOwStaphylococcus aureusTest</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>240</td></tr></table>

95% C.I. Positive Agreement: $9 8 . 8 \%$ EY (93.6 - 99.8%) Negative Agreement: $1 0 0 . 0 \%$ EY $( 9 8 . 4 \% \cdot 1 0 0 . 0 \% )$

Expected Values

In the external clinical evaluation of BinaxNOw® Staphylococcus aureus Test, the overall expected rate of $s .$ aureus in blood culture was $2 6 . 2 \%$ (85/325), and among the three site populations the expected positive rate ranged from $1 6 . 9 \%$ to $4 1 . 5 \%$ .

# Analytical Reactivity

The 54 human pathogenic Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA) and American Type Culture Collection (ATCC) Staphylococcus aureus strains listed below tested positive in the BinaxNOW test.

# Staphylococcus aureus strains

<table><tr><td rowspan=1 colspan=1>Bacterium</td><td rowspan=1 colspan=1>Bacterium                  :</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus ATCC 13150</td><td rowspan=1 colspan=1>Staphylococcus aureus NRS172</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus ATCC 11632</td><td rowspan=1 colspan=1>Staphylococcus aureus NRS241</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus ATCC 14776</td><td rowspan=1 colspan=1>Staphylococcus aureus NRS245</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus ATCC 14458</td><td rowspan=1 colspan=1>Staphylococcus aureus NRS248</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus ATCC 6517</td><td rowspan=1 colspan=1>Staphylococcus aureus NRS249</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus ATCC 29737</td><td rowspan=1 colspan=1>Staphylococcus aureus NRS164</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus ATCC 29213</td><td rowspan=1 colspan=1>Staphylococcus aureus NRS165</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus ATCC 49476</td><td rowspan=1 colspan=1>Staphylococcus aureus NRS166</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus ATCC 33592</td><td rowspan=1 colspan=1>Staphylococcus aureus NRS167</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus ATCC BAA38</td><td rowspan=1 colspan=1>Staphylococcus aureus NRS168</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus ATCC 14775</td><td rowspan=1 colspan=1>Staphylococcus aureus NRS169</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus ATCC BAA43</td><td rowspan=1 colspan=1>Staphylococcus aureus NRS170</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus Lafferty</td><td rowspan=1 colspan=1>Staphylococcus aureus NRS171</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus ATCC 6538P</td><td rowspan=1 colspan=1>Staphylococcus aureus NRS173</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus ATCC BAA1026</td><td rowspan=1 colspan=1>Staphylococcus aureus NRS174</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus ATCC BAA977</td><td rowspan=1 colspan=1>Staphylococcus aureus NRS175</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus ATCC BAA39</td><td rowspan=1 colspan=1>Staphylococcus aureus NRS176</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus ATCC51153</td><td rowspan=1 colspan=1>Staphylococcus aureus NRS177</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus ATCC 700789</td><td rowspan=1 colspan=1>Staphylococcus aureus NRS382 (USA100)</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus ATCC BAA41</td><td rowspan=1 colspan=1>Staphylococcus aureus NRS383 (USA200)</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus ATCC 33591</td><td rowspan=1 colspan=1>Staphylococcus aureus NRS384 (USA300)</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus ATCC BAA44</td><td rowspan=1 colspan=1>Staphylococcus aureus NRS123 (USA400)</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus ATCC 700698</td><td rowspan=1 colspan=1>Staphylococcus aureus NRS385 (USA500)</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus ATCC 43300</td><td rowspan=1 colspan=1>Staphylococcus aureus NRS22 (USA600)</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus ATCC 700699</td><td rowspan=1 colspan=1>Staphylococcus aureus NRS386 (USA700)</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus NRS193</td><td rowspan=1 colspan=1>Staphylococcus aureus NRS387 (USA800)</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus NRS194</td><td rowspan=1 colspan=1>Staphylococcus aureus NRS192</td></tr></table>

# Analytical Specificity (Cross-Reactivity)

To determine the analytical specificity of the BinaxNOW® Staphylococcus aureus Test, coagulaseStyl ya  onyl shB Test. All strains in the tables below tested negative.

# Coagulase-negative Staphylococcus strains

<table><tr><td>Bacterium</td></tr><tr><td>Staphylococcus auricularis ATCC 33753</td></tr></table>

BinaxNOW® Staphylococcus aureus Test Confidential   
510(k) Notification k090964   
Rev. 12/09/09

<table><tr><td rowspan=1 colspan=1>Staphylococcus capitis ATCC 35661</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus caprae ATCC 51548</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus cohnii ATCC 29972</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus delphini ATCC 49171</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus epidermidis ATCC 700579</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus haemolyticus ATCC 29970</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus hominis ATCC 27844</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus hyicus ATCC 11249</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus intermedius ATCC 29663</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus kloosii ATCC 43959</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus lentus ATCC 700403</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus lugdunensis ATCC 43809</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus lutrae ATCC 700373</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus pasteuri ATCC 51128</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus pseudintermedius ATCC 49444</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus pulvereri ATCC 51698</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus saprophyticus ATCC 35552</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus schleiferi ATCC 43808</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus sciuri ATCC 49575</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus stimulans ATCC 27851</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus vitulinus ATCC 51162</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus warneri ATCC 49454</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus xylosus ATCC 49148</td></tr></table>

Non- Staphylococcal Strains   

<table><tr><td colspan="1" rowspan="1">Bacterium9</td><td colspan="1" rowspan="1">Bacterium                        :</td></tr><tr><td colspan="1" rowspan="1">Acinetobacter calcoaceticus ATCC 51432</td><td colspan="1" rowspan="1">Pasteurella multocida ATCC 51687</td></tr><tr><td colspan="1" rowspan="1">Aerococcus urinae ATCC 700306</td><td colspan="1" rowspan="1">Pediococcus acidilactici ATCC 12697</td></tr><tr><td colspan="1" rowspan="1">Aerococcus viridans ATCC 10400</td><td colspan="1" rowspan="1">Peptostreptococcus anaerobius ATCC 27337</td></tr><tr><td colspan="1" rowspan="1">Aeromonas hydrophilia ATCC 35654</td><td colspan="1" rowspan="1">Planococcus citreus ATCC 14404</td></tr><tr><td colspan="1" rowspan="1">Bacillus cereus ATCC 11778</td><td colspan="1" rowspan="1">Proteus mirabilis ATCC 7002</td></tr><tr><td colspan="1" rowspan="1">Bacillus subtilis ATCC 6633</td><td colspan="1" rowspan="1">Proteus vulgaris ATCC 33420</td></tr><tr><td colspan="1" rowspan="1">Bacteroides fragilis ATCC 23745</td><td colspan="1" rowspan="1">Providencia stuartii ATCC 49809</td></tr><tr><td colspan="1" rowspan="1">Beta strep group F ATCC 12392</td><td colspan="1" rowspan="1">Pseudomonas aeruginosa ATCC 15442</td></tr><tr><td colspan="1" rowspan="1">Burkholdaria cepacia ATCC 25416-T</td><td colspan="1" rowspan="1">Pseudomonas fluorescens ATCC 49271</td></tr><tr><td colspan="1" rowspan="1">Citrobacter freundii ATCC 8090</td><td colspan="1" rowspan="1">Pseudomonas putida ATCC 49128</td></tr><tr><td colspan="1" rowspan="1">Clostridium septicum ATCC 12646</td><td colspan="1" rowspan="1">Rhodococcus equi ATCC 10146</td></tr><tr><td colspan="1" rowspan="1">Clostridium sordelli ATCC 9714</td><td colspan="1" rowspan="1">Salmonella adelaide ATCC 10718</td></tr><tr><td colspan="1" rowspan="1">Corynebacterium amycolatum ATCC 49368</td><td colspan="1" rowspan="1">Serratia marcescens ATCC 13880</td></tr><tr><td colspan="1" rowspan="1">Corynebacterium diphtheriae ATCC 13812</td><td colspan="1" rowspan="1">Stenotrophomonas maltophilia ATCC 13637-T</td></tr><tr><td colspan="1" rowspan="1">Corynebacterium glutamicum ATCC 13869</td><td colspan="1" rowspan="1">Stomatococcus (Rothia mucilaginosa) ATCC 25296</td></tr><tr><td colspan="1" rowspan="1">Corynebacterium jeikeium ATCC 43734</td><td colspan="1" rowspan="1">Stomatococcus (Rothia mucilaginosa) ATCC 49040</td></tr><tr><td colspan="1" rowspan="1">Corynebacterium pseudodiptheriticum ATCC10700-T</td><td colspan="1" rowspan="1">Stomatococcus (Rothia mucilaginosa) ATCC 49041</td></tr><tr><td colspan="1" rowspan="1">Corynebacterium urealyticum ATCC 43042</td><td colspan="1" rowspan="1">Stomatococcus (Rothia mucilaginosa) ATCC 49042</td></tr><tr><td colspan="1" rowspan="1">Corynebacterium xerosus ATCC 7711</td><td colspan="1" rowspan="1">Streptococcus agalactiae (Beta Strep Group B) ATCC13813</td></tr><tr><td colspan="1" rowspan="1">Enterobacter aerogenes ATCC 35029</td><td colspan="1" rowspan="1">Streptococcus anginosis (milleri) ATCC 33397</td></tr><tr><td colspan="1" rowspan="1">Enterobacter cloacae ATCC 49141</td><td colspan="1" rowspan="1">Streptococcus dysgalactiae (Group C) ATCC 12388</td></tr><tr><td colspan="1" rowspan="1">Enterococcus avium ATCC 49462</td><td colspan="1" rowspan="1">Streptococcus dysgalactiae (Group G) ATCC 12394</td></tr><tr><td colspan="1" rowspan="1">Enterococcus casseliflavus ATCC 12817</td><td colspan="1" rowspan="1">Streptococcus intermedius (milleri) ATCC 27355</td></tr><tr><td colspan="1" rowspan="1">Enterococcus durans ATCC 49135</td><td colspan="1" rowspan="1">Streptococcus mitis ATCC 49456</td></tr><tr><td colspan="1" rowspan="1">Enterococcus faecalis ATCC 49474</td><td colspan="1" rowspan="1">Streptococcus mutans ATCC 25175</td></tr><tr><td colspan="1" rowspan="1">Enterococcus faecium ATCC 12952</td><td colspan="1" rowspan="1">Streptococcus pasteurans (bovis) ATCC 49133</td></tr><tr><td colspan="1" rowspan="1">Enterococcus gallinarum ATCC 49608</td><td colspan="1" rowspan="1">Streptococcus pneumoniae ATCC 33400</td></tr><tr><td colspan="1" rowspan="1">Enterococcus hirae ATCC 10541</td><td colspan="1" rowspan="1">Streptococcus pneumoniae ATCC 39938</td></tr><tr><td colspan="1" rowspan="1">Enterococcus mundtii ATCC 43187</td><td colspan="1" rowspan="1">Streptococcus pneumoniae ATCC 49136</td></tr><tr><td colspan="1" rowspan="1">Enterococcus raffinosus ATCC 49464</td><td colspan="1" rowspan="1">Streptococcus pneumoniae ATCC 49619</td></tr><tr><td colspan="1" rowspan="1">Escherichia coli ATCC 10798</td><td colspan="1" rowspan="1">Streptococcus pneumoniae ATCC 51937</td></tr><tr><td colspan="1" rowspan="1">Gemella spp. bergeri ATCC 700627</td><td colspan="1" rowspan="1">Streptococcus pneumoniae ATCC 51938</td></tr><tr><td colspan="1" rowspan="1">Haemophilus influenzae ATCC 49247</td><td colspan="1" rowspan="1">Streptococcus pneumoniae ATCC 6301</td></tr><tr><td colspan="1" rowspan="1">Klebsiella oxytoca ATCC 49131</td><td colspan="1" rowspan="1">Streptococcus pneumoniae ATCC SSI-1</td></tr><tr><td colspan="1" rowspan="1">Klebsiella pneumoniae ATCC 49472</td><td colspan="1" rowspan="1">Streptococcus pneumoniae ATCC SSI-10A</td></tr><tr><td colspan="1" rowspan="1">Lactobacillus casei ATCC 393</td><td colspan="1" rowspan="1">Streptococcus pneumoniae ATCC SS1-14</td></tr><tr><td colspan="1" rowspan="1">Lactococcus spp.garvieae ATCC 49157</td><td colspan="1" rowspan="1">Streptococcus pneumoniae ATCC SSI-7F</td></tr><tr><td colspan="1" rowspan="1">Leuconostoc mesenteriodes ATCC 10877</td><td colspan="1" rowspan="1">Streptococcus pyogenes, group A ATCC 12384</td></tr><tr><td colspan="1" rowspan="1">Listeria monocytogenes ATCC 19115</td><td colspan="1" rowspan="1">Streptococcus salivarius ATCC 13419</td></tr><tr><td colspan="1" rowspan="1">Macrococcus caseolyticus (formerly Staph cohniisubsp. cohnii) ATCC 35662</td><td colspan="1" rowspan="1">Streptococcus salivarius ATCC 13419</td></tr><tr><td colspan="1" rowspan="1">Micrococcus luteus ATCC 27141</td><td colspan="1" rowspan="1">Yeasts                              ," </td></tr><tr><td colspan="1" rowspan="1">Moraxella catarrhalis ATCC 25238</td><td colspan="1" rowspan="1">Candida albicans ATCC 60193</td></tr><tr><td colspan="1" rowspan="1">Morganella morganii ATCC 25830-T</td><td colspan="1" rowspan="1">Candida glabrata ATCC 66032</td></tr><tr><td colspan="1" rowspan="1">Neisseria meningitides (serogroup A) ATCC13077</td><td colspan="1" rowspan="1">Candida tropicalis ATCC 750</td></tr><tr><td colspan="1" rowspan="1">Neisseria sicca ATCC 9913</td><td></td></tr></table>

# Interfering Substances:

None of the 20 potentially interfering substances listed below produced false results in the BinaxNOw Staphylococcus aureus test.

<table><tr><td rowspan=1 colspan=1>Anti-InflammatoryDrugs</td><td rowspan=1 colspan=1>Test Concentration</td><td rowspan=1 colspan=1>Endogenous Blood Components</td><td rowspan=1 colspan=1>Test Concentration</td></tr><tr><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>1324 μmol/L</td><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>2g/L</td></tr><tr><td rowspan=1 colspan=1>Acetylsalicyclic acid</td><td rowspan=1 colspan=1>3.62 mmol/L</td><td rowspan=1 colspan=1>Triglyceride sera</td><td rowspan=1 colspan=1>37 mmol/L</td></tr><tr><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>2425 μmol/L</td><td rowspan=1 colspan=1>Conjugated bilirubin</td><td rowspan=1 colspan=1>342 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Antibiotics      E</td><td rowspan=1 colspan=1>Test Concentration</td><td rowspan=1 colspan=1>Unconjugated bilirubin</td><td rowspan=1 colspan=1>342 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Amoxicillin</td><td rowspan=1 colspan=1>206 μmol/L</td><td rowspan=1 colspan=1>γ- globulin</td><td rowspan=1 colspan=1>120g/L</td></tr><tr><td rowspan=1 colspan=1>Cephalexin</td><td rowspan=1 colspan=1>337 μmol/L</td><td rowspan=1 colspan=1>Anti-coagulant       </td><td rowspan=1 colspan=1>Test Concentration</td></tr><tr><td rowspan=1 colspan=1>Chloramphenicol</td><td rowspan=1 colspan=1>155 μmol/L</td><td rowspan=1 colspan=1>Sodium Polyanetholesulfonate (SPS)</td><td rowspan=1 colspan=1>1%</td></tr><tr><td rowspan=1 colspan=1>Ciprofloxacin</td><td rowspan=1 colspan=1>30.2 μmol/L</td><td rowspan=3 colspan=2></td></tr><tr><td rowspan=1 colspan=1>Erythromycin</td><td rowspan=1 colspan=1>81.6 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Gentamicin</td><td rowspan=1 colspan=1>21 umol/L</td></tr></table>

BinaxNOW® Staphylococcus aureus Test Confidential   
$5 1 0 ( \mathrm { k } )$ Notification k090964   
Rev. 12/09/09

<table><tr><td rowspan=1 colspan=1>Tetracycline</td><td rowspan=1 colspan=1>34 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Sulfisoxazole</td><td rowspan=1 colspan=1>1.12 mmol/L</td></tr><tr><td rowspan=1 colspan=1>Sulfamethoxazole</td><td rowspan=1 colspan=1>1.58 mmol/L</td></tr><tr><td rowspan=1 colspan=1>Trimethoprim</td><td rowspan=1 colspan=1>138 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Vancomycin</td><td rowspan=1 colspan=1>69 μmol/L</td></tr></table>

Analytical Sensitivity: The analytical limit of detection of the BinaxNOW® Staphylococcus aureus Test is $5 . 4 2 \times 1 0 ^ { 8 }$ cells/mL.

<table><tr><td rowspan=1 colspan=1>. BacterialConcentrationcells/mL</td><td rowspan=1 colspan=1>NumberDetected</td><td rowspan=1 colspan=1>%Detection</td></tr><tr><td rowspan=1 colspan=1>2.71 x 10}$</td><td rowspan=1 colspan=1>26/26</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>5.42 x 108</td><td rowspan=1 colspan=1>25/26</td><td rowspan=1 colspan=1>96</td></tr><tr><td rowspan=1 colspan=1>1.14x 108</td><td rowspan=1 colspan=1>15/26</td><td rowspan=1 colspan=1>75</td></tr><tr><td rowspan=1 colspan=1>7.07 x 107</td><td rowspan=1 colspan=1>10/26</td><td rowspan=1 colspan=1>50</td></tr></table>

# Reproducibility Study:

A study of the BinaxNOw® Staphylococcus aureus Test was conducted at 3 separate sites using panels of blind coded specimens containing negative and positive samples. Participants tested each sample twice on 5 different days. There was $9 8 \%$ (588/600) agreement with expected test results, with no significant differences within run (replicates tested by one operator), between run (5 different days), between sites (3 sites), or between operators (6 operators).

Binax, Inc.   
c/o Ms. Suzanne Vogel   
Clinical Affairs Inverness Medical 10 Southgate Road   
Scarborough, ME 04074

Re: k090964

Trade Name: BinaxNow $\textsuperscript { \textregistered }$ Staphylococcus Aureus Test   
Regulation Number: 21 CFR $\ S 8 6 6 . 2 6 6 0$ E   
Regulation Name: Microorganism differentiation and identification device   
Regulatory Class: Class I   
Product Codes: JWX   
Dated: October 23, 2009   
Received: October 30, 2009

Dear Ms. Vogel:

We have reviewed your Section $5 1 0 ( \mathbf { k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21

CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html

Sincerely yours,

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

510(k) Number: 090964

Device Name: BinaxNOW® Staphylococcus aureus Test

Indications for Use:

The BinaxNOW® Staphylococcus aureus Test is a qualitative, in vitro immunochromatographic assay for the presumptive identification of Staphylococcus aureus. The test is performed directly on blood culture samples positive for Gram-positive cocci in clusters. The BinaxNOw Staphylococcus aureus Test is not intended to diagnose Staphylococcus aureus nor to guide or monitor treatment for Staphylococcus aureus infections. Subculturing positive blood cultures is necessary to recover organisms for susceptibility testing and/or differentiation of mixed growth.

Prescription Use √ (Part 21 CFR 801 Subpart D)

(PLEASE DO NOT WRITE BELOW THIS LINE- CONTINUE ON ANOTHER PAGE IF NEEDED)

Office of In Vitro Diagnostic Device   
Evaluation and Safety   
510(k) k090964